<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01591317</url>
  </required_header>
  <id_info>
    <org_study_id>11990</org_study_id>
    <secondary_id>H7T-FW-TACQ</secondary_id>
    <nct_id>NCT01591317</nct_id>
  </id_info>
  <brief_title>Study of Prasugrel in Korean Healthy Male Volunteers</brief_title>
  <official_title>Single and Multiple Dose Pharmacokinetics and Pharmacodynamics of Prasugrel (LY640315) in Korean Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate how the body processes prasugrel and how
      prasugrel affects blood clotting in healthy Korean men. Three different dosing regimens of
      prasugrel will be given. Information on side effects will also be collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of Prasugrel's Active Metabolite R-138727 During Loading Dose</measure>
    <time_frame>Day 1 predose up to 24 hours post dose</time_frame>
    <description>AUC from time zero to the last quantifiable plasma concentration (tlast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) for Prasugrel's Active Metabolite R-138727 During Loading Dose</measure>
    <time_frame>Day 1 predose up to 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of Prasugrel's Active Metabolite R-138727 During Loading Dose</measure>
    <time_frame>Day 1 predose up to 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of Prasugrel's Active Metabolite R-138727 During Maintenance Dose</measure>
    <time_frame>Day 11 predose to 24 hours post dose</time_frame>
    <description>AUC from time zero to the last quantifiable plasma concentration (tlast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) for Prasugrel's Active Metabolite R-138727 During Maintenance Dose</measure>
    <time_frame>Day 11 predose to 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of Prasugrel's Active Metabolite R-138727 During Maintenance Dose</measure>
    <time_frame>Day 11 predose to 24 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation</measure>
    <time_frame>Predose up to 24 hours post dose on Day 12</time_frame>
    <description>ADP-induced PRU represents the rate and extent of ADP-stimulated platelet aggregation and serves as a biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Inhibition of Verify Now (VN)-P2Y12 Reaction Units (PRU)</measure>
    <time_frame>Predose up to 24 hours post dose on Day 12</time_frame>
    <description>PRU device reported VerifyNow percent inhibition is reported by Accumetrics VerifyNow™ P2Y12 (VN-P2Y12) assay, a point-of-care device that measures platelet aggregation with single-use, disposable cartridges</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Prasugrel - 60 mg/10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel - 30 mg/7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel - 30 mg/5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Tablets orally</description>
    <arm_group_label>Prasugrel - 60 mg/10 mg</arm_group_label>
    <arm_group_label>Prasugrel - 30 mg/7.5 mg</arm_group_label>
    <arm_group_label>Prasugrel - 30 mg/5 mg</arm_group_label>
    <other_name>LY640315</other_name>
    <other_name>Effient</other_name>
    <other_name>Efient</other_name>
    <other_name>Prasita</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy males, as determined by medical history and physical examination.

          -  Are between the ages of 20 and 45 years, inclusive.

          -  Have a body mass index (BMI) of 19 kg/m^2 to 27 kg/m^2, inclusive, at screening.

        Exclusion Criteria:

          -  Are currently enrolled in, or discontinued within the last 60 days from a clinical
             trial involving an investigational drug or device, or are concurrently enrolled in any
             other type of medical research judged not to be scientifically or medically compatible
             with this study.

          -  Have known allergies to prasugrel or related compounds.

          -  Are persons who have previously completed or withdrawn from this study or any other
             study investigating prasugrel.

          -  Self-reported history of significant bleeding from trauma (for example, prolonged
             bleeding after tooth extraction).

          -  History of major surgery within 3 months of screening or planned surgery within 14
             days after the last day of dosing.

          -  Have a platelet count of &lt;100,000/(cubic millimeters) mm^3 at the time of screening.

          -  Have tested positive for fecal occult blood at screening.

          -  Have significant prolongation of prothrombin time (PT) or activated partial
             thromboplastin time (APTT) at screening.

          -  Have a clinically significant abnormality following the investigator's review of the
             physical examination, electrocardiogram (ECG)and clinical (safety) laboratory tests at
             screening.

          -  Personal or first-degree family history of coagulation or bleeding disorders (that is,
             hematemesis, melena, severe or recurrent epistaxis, hemoptysis, gastrointestinal
             ulcers, hemorrhage, clinically overt hematuria or intracranial hemorrhage) or
             reasonable suspicion of vascular malformations, for example, cerebral hemorrhage,
             aneurysm or premature stroke (cerebrovascular accident [CVA] &lt;65 years of age).

          -  Have significant active hematological disease and/or whole blood donation of more than
             400 mL within the last 2 months and component blood donation within the last month.

          -  Volunteers who have an average weekly alcohol intake that exceeds 21 units per week or
             volunteers unwilling to adhere to study alcohol restrictions during the study (1 unit
             = 360 mL of beer; 150 mL of wine; 45 mL of distilled spirits).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2012</study_first_posted>
  <results_first_submitted>September 4, 2012</results_first_submitted>
  <results_first_submitted_qc>September 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 4, 2012</results_first_posted>
  <last_update_submitted>September 4, 2012</last_update_submitted>
  <last_update_submitted_qc>September 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prasugrel - 60 mg/10 mg</title>
          <description>Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days</description>
        </group>
        <group group_id="P2">
          <title>Prasugrel - 30 mg/7.5 mg</title>
          <description>Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days</description>
        </group>
        <group group_id="P3">
          <title>Prasugrel - 30 mg/5 mg</title>
          <description>Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prasugrel - 60 mg/10 mg</title>
          <description>Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days</description>
        </group>
        <group group_id="B2">
          <title>Prasugrel - 30 mg/7.5 mg</title>
          <description>Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days</description>
        </group>
        <group group_id="B3">
          <title>Prasugrel - 30 mg/5 mg</title>
          <description>Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="5.3"/>
                    <measurement group_id="B2" value="25.9" spread="5.2"/>
                    <measurement group_id="B3" value="26.0" spread="4.1"/>
                    <measurement group_id="B4" value="26.7" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of Prasugrel's Active Metabolite R-138727 During Loading Dose</title>
        <description>AUC from time zero to the last quantifiable plasma concentration (tlast)</description>
        <time_frame>Day 1 predose up to 24 hours post dose</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg loading dose given once orally</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg loading dose given once orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of Prasugrel's Active Metabolite R-138727 During Loading Dose</title>
          <description>AUC from time zero to the last quantifiable plasma concentration (tlast)</description>
          <population>All randomized participants</population>
          <units>nanogram times hour/milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600" spread="16"/>
                    <measurement group_id="O2" value="283" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Maximum Concentration (Cmax) for Prasugrel's Active Metabolite R-138727 During Loading Dose</title>
        <time_frame>Day 1 predose up to 24 hours post dose</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg loading dose given once orally</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg loading dose given once orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Maximum Concentration (Cmax) for Prasugrel's Active Metabolite R-138727 During Loading Dose</title>
          <population>All randomized participants</population>
          <units>nanogram/milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="498" spread="41"/>
                    <measurement group_id="O2" value="271" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of Prasugrel's Active Metabolite R-138727 During Loading Dose</title>
        <time_frame>Day 1 predose up to 24 hours post dose</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg loading dose given once orally</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg loading dose given once orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of Prasugrel's Active Metabolite R-138727 During Loading Dose</title>
          <population>All randomized participants</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.25" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.25" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation</title>
        <description>ADP-induced PRU represents the rate and extent of ADP-stimulated platelet aggregation and serves as a biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition</description>
        <time_frame>Predose up to 24 hours post dose on Day 12</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel - 60 mg/10 mg</title>
            <description>Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel - 30 mg/7.5 mg</title>
            <description>Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel - 30 mg/5 mg</title>
            <description>Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation</title>
          <description>ADP-induced PRU represents the rate and extent of ADP-stimulated platelet aggregation and serves as a biomarker of clinical efficacy, with lower values indicating greater P2Y12 platelet inhibition</description>
          <population>All randomized participants</population>
          <units>PRU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290" spread="36.2"/>
                    <measurement group_id="O2" value="273" spread="39.6"/>
                    <measurement group_id="O3" value="297" spread="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 0.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" spread="120"/>
                    <measurement group_id="O2" value="107" spread="95.5"/>
                    <measurement group_id="O3" value="172" spread="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="18.9"/>
                    <measurement group_id="O2" value="19.0" spread="42.6"/>
                    <measurement group_id="O3" value="46.0" spread="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="2.16"/>
                    <measurement group_id="O2" value="7.00" spread="11.3"/>
                    <measurement group_id="O3" value="20.1" spread="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="1.89"/>
                    <measurement group_id="O2" value="3.10" spread="1.73"/>
                    <measurement group_id="O3" value="12.1" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.10" spread="9.52"/>
                    <measurement group_id="O2" value="5.10" spread="2.56"/>
                    <measurement group_id="O3" value="26.9" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="51.4"/>
                    <measurement group_id="O2" value="35.1" spread="25.0"/>
                    <measurement group_id="O3" value="121" spread="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11, predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" spread="61.9"/>
                    <measurement group_id="O2" value="26.4" spread="27.7"/>
                    <measurement group_id="O3" value="123" spread="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" spread="26.7"/>
                    <measurement group_id="O2" value="27.2" spread="31.8"/>
                    <measurement group_id="O3" value="107" spread="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of Prasugrel's Active Metabolite R-138727 During Maintenance Dose</title>
        <description>AUC from time zero to the last quantifiable plasma concentration (tlast)</description>
        <time_frame>Day 11 predose to 24 hours post dose</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 10 mg</title>
            <description>Prasugrel 10 mg once a day orally for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 7.5 mg</title>
            <description>Prasugrel 7.5 mg once a day orally for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 5 mg</title>
            <description>Prasugrel 5 mg once a day orally for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of Prasugrel's Active Metabolite R-138727 During Maintenance Dose</title>
          <description>AUC from time zero to the last quantifiable plasma concentration (tlast)</description>
          <population>All randomized participants</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.1" spread="24"/>
                    <measurement group_id="O2" value="58.4" spread="21"/>
                    <measurement group_id="O3" value="38.3" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Maximum Concentration (Cmax) for Prasugrel's Active Metabolite R-138727 During Maintenance Dose</title>
        <time_frame>Day 11 predose to 24 hours post dose</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 10 mg</title>
            <description>Prasugrel 10 mg once a day orally for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 7.5 mg</title>
            <description>Prasugrel 7.5 mg once a day orally for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 5 mg</title>
            <description>Prasugrel 5 mg once a day orally for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Maximum Concentration (Cmax) for Prasugrel's Active Metabolite R-138727 During Maintenance Dose</title>
          <population>All randomized participants</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" spread="36"/>
                    <measurement group_id="O2" value="61.9" spread="37"/>
                    <measurement group_id="O3" value="41.0" spread="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of Prasugrel's Active Metabolite R-138727 During Maintenance Dose</title>
        <time_frame>Day 11 predose to 24 hours post dose</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 10 mg</title>
            <description>Prasugrel 10 mg once a day orally for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 7.5 mg</title>
            <description>Prasugrel 7.5 mg once a day orally for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 5 mg</title>
            <description>Prasugrel 5 mg once a day orally for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of Prasugrel's Active Metabolite R-138727 During Maintenance Dose</title>
          <population>All randomized participants</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.25" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.25" upper_limit="0.52"/>
                    <measurement group_id="O3" value="0.38" lower_limit="0.25" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Inhibition of Verify Now (VN)-P2Y12 Reaction Units (PRU)</title>
        <description>PRU device reported VerifyNow percent inhibition is reported by Accumetrics VerifyNow™ P2Y12 (VN-P2Y12) assay, a point-of-care device that measures platelet aggregation with single-use, disposable cartridges</description>
        <time_frame>Predose up to 24 hours post dose on Day 12</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel - 60 mg/10 mg</title>
            <description>Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel - 30 mg/7.5 mg</title>
            <description>Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel - 30 mg/5 mg</title>
            <description>Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Inhibition of Verify Now (VN)-P2Y12 Reaction Units (PRU)</title>
          <description>PRU device reported VerifyNow percent inhibition is reported by Accumetrics VerifyNow™ P2Y12 (VN-P2Y12) assay, a point-of-care device that measures platelet aggregation with single-use, disposable cartridges</description>
          <population>All randomized participants</population>
          <units>Percent inhibition of PRU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.90" spread="10.9"/>
                    <measurement group_id="O2" value="6.80" spread="5.57"/>
                    <measurement group_id="O3" value="9.90" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 0.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9" spread="35.5"/>
                    <measurement group_id="O2" value="66.9" spread="28.9"/>
                    <measurement group_id="O3" value="48.8" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" spread="6.00"/>
                    <measurement group_id="O2" value="94.2" spread="13.9"/>
                    <measurement group_id="O3" value="86.9" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" spread="0.568"/>
                    <measurement group_id="O2" value="97.7" spread="3.47"/>
                    <measurement group_id="O3" value="94.0" spread="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" spread="0.632"/>
                    <measurement group_id="O2" value="99.1" spread="0.738"/>
                    <measurement group_id="O3" value="96.8" spread="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" spread="2.94"/>
                    <measurement group_id="O2" value="98.3" spread="0.675"/>
                    <measurement group_id="O3" value="92.0" spread="9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" spread="15.7"/>
                    <measurement group_id="O2" value="87.6" spread="8.82"/>
                    <measurement group_id="O3" value="63.6" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11, predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.5" spread="18.4"/>
                    <measurement group_id="O2" value="91.2" spread="9.07"/>
                    <measurement group_id="O3" value="64.8" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" spread="7.43"/>
                    <measurement group_id="O2" value="91.0" spread="10.0"/>
                    <measurement group_id="O3" value="67.0" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prasugrel - 60 mg/10 mg</title>
          <description>Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days</description>
        </group>
        <group group_id="E2">
          <title>Prasugrel - 30 mg/7.5 mg</title>
          <description>Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days</description>
        </group>
        <group group_id="E3">
          <title>Prasugrel - 30 mg/5 mg</title>
          <description>Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vessel puncture site paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sputum retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

